4-(1-1,2,4-三唑基)苯甲醛 | 27996-86-7

• 物质功能分类: 有机原料 - 醛类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-(1-1,2,4-三唑基)苯甲醛
• 中文别名: 4-(1氢-1,2,4-三唑-1-基)苯甲醛；4-(1H-1,2,4-噻唑-1-基)苯甲醛；1-(4-甲酰基苯基)-1H-1,2,4-三唑；1-(4-甲酰基苯基)-1,2,4-三唑；4-(1,2,4-三唑-1-基)苯甲醛
• 英文名称: 4-(1H-1,2,4-triazol-1-yl)benzaldehyde
• 英文别名: 4-(1,2,4-triazol-1-yl)benzaldehyde；4-(1-1,2,4-triazolyl)benzaldehyde；4-(1H-1,2,4-triazole-1-yl)benzaldehyde
• CAS: 27996-86-7
• 化学式: C₉H₇N₃O
• mdl: MFCD02681969
• 分子量: 173.174
• InChiKey: TVEJNWMWDIXPAX-UHFFFAOYSA-N

物化性质

• 熔点：
  147 °C
• 沸点：
  369.2±44.0 °C(Predicted)
• 密度：
  1.25±0.1 g/cm3(Predicted)
• 溶解度：
  微溶于在甲醇中

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  47.8
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 危险类别码：
  R22
• 海关编码：
  2933990090
• 安全说明：
  S22,S26,S36/37/39
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存放于惰性气体中，避免与空气接触。

SDS

Name:	4-(1h-1 2 4-triazol-1-yl)benzaldehyde 95+% Material Safety Data Sheet
Synonym:
CAS:	27996-86-7

Section 1 - Chemical Product MSDS Name:4-(1h-1 2 4-triazol-1-yl)benzaldehyde 95+% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
27996-86-7	4-(1H-1,2,4-Triazol-1-yl)benzaldehyde	95+%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 27996-86-7: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: pale yellow
Odor: characteristic odor
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H7N3O
Molecular Weight: 173.17

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, amines.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 27996-86-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-(1H-1,2,4-Triazol-1-yl)benzaldehyde - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 27996-86-7: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 27996-86-7 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 27996-86-7 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

4-(1-1,2,4-三唑基)苯甲醛是一种有用的研宄化学品，常用于有机合成和其他化学过程中。

反应信息

• 作为反应物：
  描述：

  4-(1-1,2,4-三唑基)苯甲醛 在 sodium hydrogensulfite 作用下， 以 乙醇 、 水 为溶剂， 反应 1.0h， 生成
  参考文献：
  名称：

  新型2-芳基苯并咪唑衍生物作为治疗阿尔茨海默氏病的多靶点药物

  摘要：

  这项研究描述了合成，药理学评估，包括乙酰胆碱酯酶（AChE）/丁酰胆碱酯酶（BChE）抑制，β淀粉样蛋白（Aβ）抗聚集和神经保护作用，以及新型2-（4-取代苯基）-1 H的分子模型-苯并咪唑衍生物。这些衍生物是通过将邻苯二胺与羟基（4-取代的苯基）甲磺酸钠盐环合而合成的。体外研究表明，大多数目标化合物对BChE表现出显着的抑制活性（IC 50：13.60–95.44 µM）。其中3d和3g-i对具有IC 50的BChE也表现出高选择性（SI≥35.7）值分别为39.56、13.60、14.45和15.15 µM。根据分子模型研究，可以假定这些化合物能够到达BChE的催化位点，但不能到达AChE的催化位点。随后检查了具有BChE抑制作用的化合物的Aβ抗聚集和神经保护活性。在这些化合物中，3d抑制了Aβ1–40的聚集，并表现出了对H 2 O 2诱导的和Aβ1–40诱导的细胞死亡的显着神经保护作

  DOI：

  10.1007/s00044-017-1874-1
• 作为产物：
  描述：

  4-(1,2,4-三唑-1-基)苯甲醇 在 pyridinium chlorochromate 作用下， 以 二氯甲烷 为溶剂， 反应 1.5h， 以49%的产率得到4-(1-1,2,4-三唑基)苯甲醛
  参考文献：
  名称：

  Aromatic hydrazides as specific inhibitors of bovine serum amine oxidase

  摘要：

  New hydrazides were synthesized in search for specific inhibitors of bovine serum amine oxidase: a series of benzoic and phenylacetic acid hydrazides containing the 1H-imidazol-1-yl or the 1H-imidazol-1-ylmethyl group as (o, m, p)-substituent in the phenyl ring; an analogous series of p-substituted phenylhydrazides with 5 or 6-membered heterocyclic ring as substituent, and a series of similar phenylpropionic hydrazides. The longer and more flexible phenylacetic hydrazides, and to a somewhat lesser extent the phenylpropionic ones, were better specific inhibitors of bovine serum amine oxidase than the benzoic hydrazides, which were also bound by the enzyme with high affinity, but at a slow rate. Derivatives with p- and m -substituents were more reactive than the o-substituted ones. The chemical nature of the substituent was less important than its position in the phenyl ring and the presence of methylene spacers. These data point to the presence of a hydrophobic site at short distance from the protein carbonyl cofactor, so that simultaneous interaction of the 2 ends of the inhibitor molecule can occur at the 2 sites. The presence of the hydrophobic site was confirmed by the capability of some molecule deprived of the hydrazidic group to act as mild inhibitors. All hydrazides were less reactive by 2-3 orders of magnitude towards pig kidney diamine oxidase and FAD-dependent monoamine oxidase from rat brain mitochondria, while the other compounds showed similar inhibition power against all proteins. The specificity for the bovine enzyme seems therefore to be related to the concerted action of the 2 moieties of the inhibitor molecule.

  DOI：

  10.1016/0223-5234(92)90005-l

文献信息

• Substituent Group Variations Directing the Molecular Packing, Electronic Structure, and Aggregation-Induced Emission Property of Isophorone Derivatives
  作者：Zheng Zheng、Zhipeng Yu、Mingdi Yang、Feng Jin、Qiong Zhang、Hongping Zhou、Jieying Wu、Yupeng Tian

  DOI：10.1021/jo400116j

  日期：2013.4.5

  ring or aza-crown-ether group, with large Stokes shifts (>140 nm), have been synthesized and characterized. 1–4 display aggregation-induced emission behaviors, while dye 5 is highly emissive in solution but quenched in the solid state. It was found that the tuning of emission color of the isophorone-based compounds in the solid state could be conveniently accomplished by changing the terminal substituent

  一系列新的异佛尔酮衍生物（的1 - 5），收纳该杂环或氮杂冠醚基团，具有大的斯托克斯位移（> 140纳米），已经合成和表征。1 - 4显示聚集诱导的发射行为，而染料5在溶液中高发射性，但在固体状态下猝灭。已经发现，通过改变末端取代基可以方便地实现固态的基于异佛尔酮的化合物的发射颜色的调节。对溶液，水悬浮液和晶态的光物理性质及其关系进行了比较研究。的晶体学数据1 - 4指示相邻分子之间的多个分子间氢键键合相互作用的存在限制了分子内振动和旋转，使化合物1 - 4在固态强烈发射。使用扫描电子显微镜研究了不同水含量的颗粒的大小和生长过程，表明水悬浮液中较小的球形纳米颗粒有利于荧光发射。以上结果表明，取代基对它们的分子堆积，电子结构和聚集诱导的发射性质有很大的影响。此外，荧光细胞成像实验证明了5的潜在应用。
• Design and Synthesis of Poly(ADP-ribose) Polymerase Inhibitors: Impact of Adenosine Pocket-Binding Motif Appendage to the 3-Oxo-2,3-dihydrobenzofuran-7-carboxamide on Potency and Selectivity
  作者：Uday Kiran Velagapudi、Marie-France Langelier、Cristina Delgado-Martin、Morgan E. Diolaiti、Sietske Bakker、Alan Ashworth、Bhargav A. Patel、Xuwei Shao、John M. Pascal、Tanaji T. Talele

  DOI：10.1021/acs.jmedchem.8b01709

  日期：2019.6.13

  Poly(adenosine 5'-diphosphate-ribose) polymerase (PARP) inhibitors are a class of anticancer drugs that block the catalytic activity of PARP proteins. Optimization of our lead compound 1 (( Z)-2-benzylidene-3-oxo-2,3-dihydrobenzofuran-7-carboxamide; PARP-1 IC50 = 434 nM) led to a tetrazolyl analogue (51, IC50 = 35 nM) with improved inhibition. Isosteric replacement of the tetrazole ring with a carboxyl

  聚腺苷5'-二磷酸核糖）聚合酶（PARP）抑制剂是一类抗癌药物，可阻断PARP蛋白的催化活性。优化我们的先导化合物1（（Z）-2-亚苄基-3-氧代-2,3-二氢苯并呋喃-7-羧酰胺; PARP-1 IC50 = 434 nM）产生了四唑基类似物（51，IC50 = 35 nM）具有更好的抑制作用。用羧基等位取代四唑环（60，IC50 = 68 nM）产生了有希望的新先导，随后对其进行了优化，以获得具有有效PARP-1 IC50值（4-197 nM）的类似物。PARP酶谱分析显示，大多数化合物对PARP-2具有选择性，其IC50值可与临床抑制剂媲美。与PARP-1结合的关键抑制剂的X射线晶体结构说明了与向PARP-1腺苷结合袋延伸的类似附件的相互作用方式。化合物81，一种同工型选择性PARP-1 / -2（IC50 = 30 nM / 2 nM）抑制剂，与同基因BRCA1精制细胞相比，对乳腺
• Inhibitors of Acyl-CoA:Cholesterol <i>O</i>-Acyltransferase. 2. Identification and Structure−Activity Relationships of a Novel Series of <i>N</i>-Alkyl-<i>N</i>-(heteroaryl-substituted benzyl)-<i>N‘</i>-arylureas
  作者：Akira Tanaka、Takeshi Terasawa、Hiroyuki Hagihara、Yuri Sakuma、Noriko Ishibe、Masae Sawada、Hisashi Takasugi、Hirokazu Tanaka

  DOI：10.1021/jm9800853

  日期：1998.6.1

  tuted benzyl)-N'-arylurea and related derivatives represented by 2 and 3 have been prepared and evaluated for their ability to inhibit acyl-CoA:cholesterol O-acyltransferase in vitro and to lower plasma cholesterol levels in cholesterol-fed rats in vivo. Among these novel compounds, the type 3 series was superior. A pyrazol-3-yl group on the N-benzyl group of this trisubstituted urea (i.e. 3, Ar1 =

  制备了一系列N-烷基-N-（杂芳基取代的苄基）-N'-芳基脲和相关的衍生物（用2和3表示），并对其在体外和体外抑制酰基辅酶A：胆固醇O-酰基转移酶的能力进行了评估。降低体内胆固醇喂养大鼠的血浆胆固醇水平。在这些新型化合物中，3型系列更为出色。该三取代脲的N-苄基上的吡唑-3-基（即3，Ar1 =吡唑-3-基）被鉴定为杂芳环，提供了良好的生物活性。通过优化与N-烷基（R）和N-芳基（Ar3）的组合的结果，化合物3aq（FR186054）被确定为一种新型的口服有效ACAT抑制剂，在胆固醇喂养的大鼠中表现出有效的体外ACAT抑制活性（兔子肠道微粒体IC50 = 99 nM）和出色的降胆固醇作用，而与给药方式无关（ED50 = 0.046 mg / kg，通过饮食给药，ED50 = 0. 44 mg /通过在PEG400载体中的管饲法施用1kg）。此外，一项毒理学研究表明，以10 mg / kg
• METHYLENE LINKED QUINOLINYL MODULATORS OF RORyt
  申请人：Janssen Pharmaceutica NV

  公开号：US20150105366A1

  公开（公告）日：2015-04-16

  The present invention comprises compounds of Formula I. wherein: R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.

  本发明包括式I的化合物。 其中： R1、R2、R3、R4、R5、R6、R7、R8和R9在说明书中定义。 本发明还包括治疗或改善综合征、紊乱或疾病的方法，其中所述综合征、紊乱或疾病为类风湿性关节炎或银屑病。本发明还包括通过给予治疗有效量的至少一个权利要求1的化合物，来调节哺乳动物中RORγt活性的方法。
• [EN] METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T<br/>[FR] MODULATEURS QUINOLINYLE À LIAISON MÉTHYLÈNE DE ROR-GAMMA-T
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2015057205A1

  公开（公告）日：2015-04-23

  The present invention comprises compounds of Formula (I). wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.

  本发明包括公式(I)的化合物。其中：R1、R2、R3、R4、R5、R6、R7、R8和R9在说明书中定义。本发明还包括治疗或改善综合症、障碍或疾病的方法，其中所述综合症、障碍或疾病为类风湿性关节炎或银屑病。本发明还包括通过管理一个治疗有效量的至少一个权利要求1的化合物来调节哺乳动物中的RORγt活性的方法。